Sign In
Last checked at 
7 Apr 2014 17:03
ο»Ώ
For immediate release: 7 April 2014
Kromek Group plc ("Kromek" or "the Company")
Director / PDMR shareholding
The Company was informed today that Richard Morgan, Chairman of the Company, purchased 40,000 Ordinary Shares ("Shares") of 1p each at an average of 50p per share on 07 April 2014, representing 0.04 per cent of the Company's total issued share capital.
Mr Morgan's total holding in the Company is now 372,310 Shares of 1p each, representing 0.35 per cent of the Company's total issued share capital.
Mr Morgan is also interested in Amphion Innovations plc through his Directorship in Amphion Innovations plc which holds 12,450,420 ordinary shares in Kromek being 11.6 per cent of the Company's total issued share capital.
-ends-
Β
For further information, please contact:
Β
Kromek Group plc Arnab Basu, CEO Derek Bulmer, CFO Β | Tel: 01740 626060 |
Panmure Gordon As Nominated Adviser and Broker Corporate Finance Freddy Crossley Broking Adam Pollock/ Charles Leigh-Pemberton Β | Tel: 020 7886 2500 |
Tavistock Communications Matt Ridsdale / Andrew Dunn | Tel: 020 7920 3150 |
Β
About Kromek Group plc
Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.
The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.
Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 70 granted patents and 110 pending applications.
The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").
The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.
The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.
Currently, the Group has over a hundred full time employees across its global operations.
Follow the stocks
